Gastric Bypass Tied to Lower Pro-Inflammatory Proteins
Changes in inflammatory biomarkers are independent of magnitude of weight loss
FRIDAY, July 1 (HealthDay News) -- Laparoscopic Roux-en-Y gastric bypass surgery (RYGB) reduces pro-inflammatory biomarkers and increases the levels of anti-inflammatory proteins, according to a study published online March 24 in Surgery for Obesity and Related Diseases.
Gary D. Miller, Ph.D., from the Wake Forest University in Winston-Salem, N.C., and colleagues investigated the changes in the inflammatory biomarkers after laparoscopic RYGB in 15 morbidly obese individuals. Fasting plasma concentrations of leptin, adiponectin, C-reactive protein (CRP), interleukin-6, tumor necrosis factor (TNF)-α, and the soluble receptor 1 for TNF-α were determined at baseline and three weeks, three months, and six months following surgery.
The investigators found that the mean weight loss was 25.7 ± 4.5 percent of the overall body weight at six months. Body mass index was reduced from an average of 55.1 ± 6.6 to 40.5 ± 5.5 kg/m². A decrease in leptin, CRP, and soluble receptor 1 for TNF-α concentrations was observed, while the adiponectin levels increased by six months after surgery. Correlations between the baseline and six-month TNF-α and CRP levels were seen.
"RYGB reduced the pro-inflammatory biomarkers and increased the anti-inflammatory mediators of obesity, independent of the magnitude of weight loss," the authors write.